3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Carcinoma, Non-Small-Cell Lung
12
Neoplasms
7
Ovarian Neoplasms
6
Colorectal Neoplasms
4
Prostatic Neoplasms
3
Carcinoma, Hepatocellular
3
Uterine Cervical Neoplasms
2
Recurrence
2
Peritoneal Neoplasms
2
Lung Neoplasms
2
Glioblastoma
2
Fallopian Tube Neoplasms
2
Carcinoma, Renal Cell
2
Breast Neoplasms
2
Thyroid Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumors
1
Small Cell Lung Carcinoma
1
Rectal Neoplasms
1
Radiation Pneumonitis
1
Patients With Any Advanced Solid Tumors
1
Ovarian Diseases
1
Oligodendroglioma
1
Neuroendocrine Tumors
1
Neoplasms by Site
1
Mesothelioma, Malignant
1
Melanoma, Cutaneous Malignant
1
Malignant Solid Tumour
1
Lymphangioleiomyomatosis
1
Leukemia, Myeloid, Acute
1
Interventions
Carboplatin
27
Paclitaxel
23
Cisplatin
22
Gemcitabine
17
pembrolizumab
15
Fluorouracil
9
Pemetrexed
8
Everolimus
8
Docetaxel
8
Cetuximab
8
Radiotherapy, Intensity-Modulated
7
Radiotherapy
7
130-nm albumin-bound paclitaxel
7
Sorafenib
6
Nivolumab
6
Bevacizumab
6
Axitinib
6
epothilone B
5
Sunitinib
5
Radiation
5
Panitumumab
5
Cyclophosphamide
5
trebananib
4
reolysin
4
padeliporfin
4
lenvatinib
4
Irinotecan
4
Gefitinib
4
vosaroxin
3
volociximab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Carcinoma
×
nintedanib
×
Clear all
NCT01610869
2019-05-29
METRO-BIBF
University College, London
Phase 2
Completed
117 enrolled